key: cord-0827458-v7gt8qur
authors: Yin, Yu-Ling; Ye, Chenyu; Zhou, Fulai; Wang, Jia; Yang, Dehua; Yin, Wanchao; Wang, Ming-Wei; Xu, H. Eric; Jiang, Yi
title: Molecular basis for kinin selectivity and activation of the human bradykinin receptors
date: 2021-05-29
journal: bioRxiv
DOI: 10.1101/2021.05.27.446069
sha: 2833eed2206a2d89af363b3ad4fb4cce3786fca9
doc_id: 827458
cord_uid: v7gt8qur

Bradykinin and kallidin are endogenous kinin peptide hormones that belong to the kallikrein-kinin system and are essential to the regulation of blood pressure, inflammation, coagulation, and pain control. Des-Arg10-kallidin, the carboxy-terminal des-Arg metabolite of kallidin, and bradykinin selectively activate two G protein-coupled receptors, type 1 and type 2 bradykinin receptors (B1R and B2R), respectively. The hyperactivation of bradykinin receptors, termed “bradykinin storm”, is associated with pulmonary edema in COVID-19 patients, suggesting that bradykinin receptors are important targets for COVID-19 intervention. Here we report two G protein complex structures of B1R and B2R bound to des-Arg10-kallidin and bradykinin. Combined with functional analysis, our structures reveal the mechanism of ligand selectivity and specific activation of the bradykinin receptor. These findings also provide a framework for guiding drug design targeting bradykinin receptors for the treatment of inflammation, cardiovascular disorders, and COVID-19.

pocket 10 . Nevertheless, kinin peptides show different selectivity for bradykinin receptor subtypes. Specifically, bradykinin is one of the highest affinity kinin-derived peptides for B2R but exhibits low affinity for B1R, with over 10,000-fold selectivity for B1R [11] [12] [13] . In contrast, des-Arg 10 -kallidin displays over 100,000-fold selectivity for B1R over B2R (Fig. 1a ) [11] [12] [13] . Extensive efforts have been made in defining the pharmacophore of antagonists and the molecular basis of ligand selectivity for kinins and other non-peptides using biochemical methods and molecular modeling [14] [15] [16] [17] [18] [19] . However, the underlined mechanisms for these peptide hormone-receptor subtype selectivity remain largely unknown due to the lack of structural evidence. Given their important physiological and pathological properties, it is of great value to elucidate molecular mechanisms for peptide recognition and bradykinin receptor activation.

Here we report two cryo-electron microscopy (cryo-EM) structures of the B1R-Gq complex bound to des-Arg 10 -kallidin and the B2R-Gq complex bound to bradykinin. Combined with mutagenesis and functional analyses, our findings provide insights into specific recognition of kinin-derived peptide hormones by B1R and B2R and the molecular basis for receptor activation and Gq protein coupling.

To stabilize B1R-Gq and B2R-Gq complexes, we applied the NanoBiT tethering method, a general strategy that has been used to obtain the structures of several GPCR-G protein complexes (Extended Data Fig. 1a, b) [20] [21] [22] . An engineered Gαq chimera was generated based on the mini-Gαs/q71 scaffold with its N-terminus replaced by corresponding sequences of Gαi1 to facilitate the binding of scFv16 (Extended Data Fig. 1c) 23, 24 . This analogous approach had been used in the structure determination of the 5-HT2AR-Gq complex 25 Fig. 4) . Thus, these two structures can provide detailed structural information of the peptide-binding pockets and receptor-Gq interaction interfaces.

Bradykinin (RPPGFSPFR) occupies the orthosteric binding pocket comprising TM helices and ECLs except for TM1 and ECL3 (Extended Data Figs. 5 and 6). It presents an S-shaped overall conformation, with its C-terminus inserting deeply into the TMD core (Fig. 2a) . This S-shaped fold is stabilized by two intramolecular H-bonds between the main chain of G5 b and R10 b , as well as the backbone of S7 b and R10 b (Fig. 2b) .

The sequence of bradykinin is featured by two positively charged arginines residing at both N-and C-terminus and the majority of hydrophobic amino acids at the middle segment of the peptide. The N-terminal R2 in bradykinin (refers to R2 b ) constitutes a stabilizing polar interaction network with ECL2, TM6, and TM7. The side chain of R2 b forms polar interactions with Y201 ECL2 and E204 ECL2 . Its main chain NH group makes polar interactions with E307 7.28 and D311 7.32 , while its backbone CO group builds an H-bond with R297 6.62 (Fig.   2b ). The C-terminal R10 b is also involved in polar interactions between bradykinin and B2R.

Although the density of the guanidino group of R10 b is weak (Fig. 2a) , it is indicative that the side chain of R10 b forms an H-bond with T314 7.35 , which is supported by diminished activity of bradykinin for B2R with T314 7.35 A mutation ( Fig. 2b and Extended Data Fig. 7 and Table   2 ). Besides R2 b and R10 b , the main chain CO group of G5 b makes an H-bond with R196 4.64 , which forms a salt bridge with the free carboxylic acid group of R10 b (Fig. 2c) . The polar interaction network is essential for bradykinin-induced B2R activation since substituting R196 4.64 with alanine entirely abolishes the activity of bradykinin (Extended Data Fig. 7 and Table 2 ). P3 b , P4 b , F6 b , P8 b , and F9 b face hydrophobic environments within the B2R TMD pocket. P3 b and P4 b interact with the aromatic ring of Y201 ECL2 and Y215 ECL2 , respectively (Fig. 2c ). Y201 ECL2 , together with F121 ECL1 , make hydrophobic contact with F6 b , which is also supported by the mutagenesis analysis ( Fig. 2c and Extended Data Fig. 7 and Table 2 ). P8 b is surrounded by hydrophobic residues of TM2 (W113 2.60 ), TM3 (I137 3.32 ), and TM7 (F319 7.40 ) ( Fig. 2c) . F9 b inserts deeply into a potent hydrophobic core comprised of residues in TM2 (L106 2.53 ), TM3 (I137 3.32 ), TM5 (L228 5.42 ), TM6 (W283 6.48 and F286 6.51 ), and TM7 (Y322 7.43 ) ( Fig. 2d) . Alanine mutations of these hydrophobic residues except for I137 3.32 show a significant impact on bradykinin-induced B2R activation, indicating a potentially critical role of these hydrophobic residues near F9 b for bradykinin binding or B2R activation (Extended Data Fig. 7 and Table 2 ). Together, these detailed structural analyses provide important information to better understand the recognition mechanism of bradykinin by B2R.

Des-Arg 10 -kallidin (KRPPGFSPF) shows high selectivity for B1R over B2R. Compared with bradykinin, des-Arg 10 -kallidin shares a conserved middle segment (RPPGFSPF) and sits in an almost identical orthosteric binding pocket with a similar S-shaped conformation ( Fig. 3a and Extended Data Figs. 5 and 6). Nevertheless, distinct interactions are observed between two peptides and corresponding receptor subtypes, proving the basis for their receptor selectivity as described below.

In contrast to bradykinin, des-Arg 10 -kallidin has an additional lysine (K1 k ) at its N-terminus but lacks arginine that is located at the C-terminus of bradykinin (R10 b ) (Fig. 3b ).

Two extra intramolecular H-bonds exist between K1 k and backbone CO group of R2 k , as well as backbone CO group of P3 k and NH group of F6 k , causing a minor conformational change of des-Arg 10 -kallidin (Fig. 3b) . The additional N-terminal K1 k forms polar interaction with E273 6.58 , E287 7.28 , and D291 7.32 (Fig. 3c) . Intriguingly, these residues are conserved in B2R (D293 6.58 , E307 7.28 , and D311 7.32 , Extended Data Fig. 6 ), which may explain the comparable B2R activation potency of Lys-bradykinin relative to bradykinin 12 . Compared with R2 b in bradykinin, the equivalent R2 k in des-Arg 10 -kallidin presents distinct interactions with TM1 and ECL2. R2 k forms a cation-pi interaction with W33 1.28 of B1R, while R2 b pushes W53 1.28 away from the binding pocket owing to the steric hindrance (Fig. 3d) . Additionally, ECL2 of B1R displays a smaller shift towards the peptide-binding pocket relative to B2R, which may be attributed to the lacking a corresponding salt bridge observed between R2 b and E204 ECL2 in B2R (Fig. 3d ).

Comparison of the binding modes between the two kinin peptides provides a framework for understanding kinin peptide selectivity by B1R and B2R. The free carboxylic acid backbone of F9 k engages a positively charged binding pocket and forms electrostatic interactions with K118 3.33 and R202 5.38 in B1R, which are not conserved in B2R (Fig. 4a) . The cognate residues S138 3.33 and T224 5.38 in B2R fail to create a similar electrostatic environment, raising a hypothesis that the electrostatic pocket comprising of K118 3.33 and R202 5.38 is the determinant for selective binding of des-Arg 10 -kallidin to B1R over B2R. This hypothesis is supported by our mutagenesis studies that single or combined substitutions of K118 3.33 and R202 5.38 in B1R with serine and threonine, equivalent residues in B2R, abolished the activity of des-Arg 10 -kallidin (Fig. 4b, f and Extended Data Table 3 ). Our results are consistent with previous reports showing that K118 3.33 attracts the negative charge of the C-terminus of B1-selective peptides and serves as a key residue in the selectivity of C-terminal des-Arg kinin peptides for B1R 18, 29 .

Compared with T224 5.38 , F286 6.51 , and D293 6.58 in B2R, the cognate residues in B1R (R202 5.38 , Y266 6.51 , and E273 6.58 ) are bulkier, resulting in insufficient space for interaction with the side chain of R10 b (Fig. 4c, d) . The role of these residues in B2R selectivity for bradykinin is identified by swapping functional analysis. The triplicate swapping of T224 5.38 /F286 6.51 /D293 6.58 with the cognate residues with larger side chains in B1R significantly impaired bradykinin activity ( Fig. 4e and Extended Data Table 3 ). This finding suggests that a larger pocket comprised of T224 5.38 , F286 6.51 , and D293 6.58 is crucial to bradykinin selectivity for B2R over B1R (Fig. 4f) . Together, these data reveal the determinants of bradykinin receptor selectivity between bradykinin and des-Arg 10 -kallidin.

However, when mutating these kinin selectivity-related residues to cognate ones, only T224R mutation in B2R showed slightly increased activity of des-Arg 10 -kallidin. Other residue substitutions did not cause significantly increased activities of bradykinin and des-Arg 10 -kallidin for B1R and B2R, respectively (Extended Data Fig. 7i, j) . It seems that only swapping the residues in the electrostatic pocket in B1R or a larger pocket in B2R failed to make the two receptors possess high-affinity for kinins. Thus, we believe that the residues in these two pockets are not entirely responsible for kinin selectivity.

A structural comparison of B1R and B2R complexes to their closely related angiotensin II receptor type 1 (AT1R) in the inactive (PDB: 4YAY 30 ) and active states (PDB: 6OS0 31 ) sheds light on the basis of bradykinin receptor activation. The structural comparison demonstrates that both B1R and B2R adopt fully active conformations similar to the active AT1R (Fig. 5a) . Compared with the inactive AT1R, they show a remarkable outward displacement of the cytoplasmic end of TM6, a hallmark of class A GPCR activation, along with an inward movement of TM7 cytoplasmic end (Fig. 5a, b) 32 .

Although bradykinin and des-Arg 10 -kallidin present different binding selectivity, they may activate bradykinin receptors through a common mechanism. The side chains of F9 b and F9 k insert into a conserved hydrophobic crevice at the bottom of the peptide-binding pocket and trigger rotameric switch of W 6.48 , the toggle switch residue, which further facilitates the swing of F 6.44 and initiates the rotation of TM6 (Fig. 5c) . Meanwhile, the steric clash between F9 k /F9 b and F/Y 7.43 would drive the latter swinging away from the receptor helical core and the inward shifting of the cytoplasmic end of TM7 (Fig. 5c ). [Leu 9 , des-Arg 10 ]kallidin, in which F9 k of des-Arg 10 -kallidin is substituted with a smaller bulky amino acid (leucine), loses its agonistic activity with conversion to a B1R antagonist, supporting the critical role of F9 k in B1R activation 33,34 . The switches of W 6.48 and F/Y 7.43 further trigger the active-like conformational changes of "micro-switch" residues (toggle switch W 6.48 and PIF, DRY, and NPxxY motifs), leading to an agonism signal transduction to the cytoplasmic end of the receptor (Fig. 5c-f ).

Structural comparison of B1R and B2R with their closely related class A GPCR member AT1R in the active state (PDB: 6OS0 31 ) suggests a common mechanism of receptor activation. The bound endogenous peptide hormones des-Arg 10 -kallidin, bradykinin, and angiotensin II share conserved C-terminal phenylalanine, which inserts into the peptide-binding pockets of corresponding receptors at a comparable depth (Extended Data Fig. 9a) , suggesting that Gq-coupled receptors have the similar conformation to G11-coupled receptors. In addition, compared with these two Gq/11-coupled receptors, the helix 8 of B1R and B2R is closer to the Gβ subunit, which may be attributed to the intramolecular salt bridge formed between K 8.53 and E 2.40 (Extended Data Fig. 9b ). On the G protein side, the α5 helix of Gαq shifts 4 Å for both B1R and B2R compared with that of G11-coupled M1R (measured at Cα of Y H5.23 ) and moves half-helical turn upward towards the cytoplasmic cavity of the receptor (2 Å for B1R and 3 Å for B2R, respectively) relative to Gq-coupled 5-HT2A receptor. Meanwhile, the Gαq N-termini of B1R and B2R undergo notable shifts seen across the Gq/11-coupled class A GPCRs (Extended Data Fig. 9c ).

Bradykinin receptors are involved in various clinical symptoms and their use as therapeutic targets remains the focus of extensive investigations. Recently, decoding of the bradykinin inflammatory pathway in COVID-19, known as "bradykinin storm", highlights the implication of bradykinin receptor modulators as a potential treatment of COVID-19. In this study, we determined two Gq-coupled structures of the human B1R and B2R bound to selective kinin peptides, des-Arg 10 -kallidin and bradykinin, respectively. In combination with functional analyses, these structures enhance our understanding of the molecular basis of kinin peptides recognition and activation of B1R and B2R.

Intriguingly, it has been recently predicted that des-Arg 10 -kallidin and bradykinin show distinct V-and S-shaped conformations, respectively. These distinct conformations result in different presentations of kinin peptides' Nand C-termini toward their receptors 18 . In our structural model, bradykinin adopts an overall similar S-shaped conformation but significantly differs in the orientation of the C-terminal charged arginine (R10 b ), with an overall r.m.s.d. of 1.8 Å (Extended Data Fig. 10a) . The side chain of R10 b sits in the gap between TM6 and TM7 and forms a salt bridge with T314 7.35 . In contrast, R10 b points to TM5 and forms a salt bridge with E221 5.35 in the predicted model. It is worth noting that des-Arg 10 -kallidin in the structural model shows an entirely different conformation, presenting an S-shaped but not a V-shaped fold with an r.m.s.d. of 3.4 Å (Extended Data Fig.   10b ). Even so, the middle segment of des-Arg 10 -kallidin (P3 k -F6 k ) in both our structure and NMR model displays a similar β-turn-like conformation, which might be stabilized by the intramolecular H-bond made by backbone NH of F6 k and CO of P3 k , as observed in B1R complex structure. A des-Arg 10 -kallidin analog with the methylated amide of F6 k , which may disturb this H-bond and central β-turn, showed a 1,000-fold lower binding affinity for B1R than the native peptide, indicating the importance of this intramolecular interaction in maintaining conformation stability of des-Arg 10 -kallidin 18 . It was predicted that the C-terminal segment of bradykinin (S7 b -R10 b ) adopted a β-turn conformation, which might be one of the necessities for high affinity to B2R 17 . The β-turn constitutes a molecular basis for designing B2R ligands, including the only approved B2R antagonist icatibant 16, 17 .

Consistently, we also observed a similar β-turn conformation, which is stabilized by two intramolecular H-bonds in B2R structure. This β-turn forces F9 b inserting deeply into the TMD core and engaging with hydrophobic residues at the bottom of the B2R pocket. Our alanine mutagenesis analysis on these hydrophobic residues further supports a potential role of the β-turn conformation of bradykinin in B2R activation.

Bradykinin receptors exhibit exquisite selectivity for bradykinin and des-Arg 10 -kallidin, and our findings provide a framework to depict the subtype selectivity of kinin peptides for B1R and B2R. It was found that the residue environments surrounding C-termini amino acids of bradykinin and des-Arg 10 -kallidin are critical to such a selectivity. K118 3.33 and R202 5.38 , which constitute a positively charged pocket interacting with the free carboxylic acid group of F9 k , are determinants of the preference of des-Arg 10 -kallidin to B1R. Additionally, the H-bond between R202 5.38 and Y266 6.51 in B1R creates an inaccessible space for bradykinin.

Meanwhile, the smaller side chains of T224 5.38 , F286 6.51 , and D293 6.58 in B2R relative to equivalent residues in B1R, create a larger pocket space to accommodate R10 b , thereby revealing the molecular basis of the higher B2R selectivity by bradykinin. Coincidentally, the NMR model predicted the same H-bond between R202 5.38 and Y266 6.51 18 . A molecular modeling study on B1R and B2R also speculated that the smaller size of T 5.38 in B2R relative to cognate residue R 5.38 in B1R allows non-peptide antagonists to access an aromatic pocket composed of W 6.48 , F 6.51 , and Y 7.43 , which is inaccessible for B1R 15, 16, 19 . However, R/T 5.38 in B1R and B2R cannot hamper the engagement of kinins with this aromatic pocket, which accommodates F9 k /F9 b in our structures. Conversely, R/T 5.38 is involved in the binding of R10 b to a larger pocket in B2R, which partially determines bradykinin selectivity for B2R over B1R. Additionally, we further propose a common activation mechanism for B1R and B2R, through structural comparison with AT1R. With an in-depth knowledge about ligand selectivity and receptor activation, new opportunities will arise to design potent and efficacious modulators of B1R and B2R for the treatment of inflammation, cardiovascular disorders, and COVID-19.

protein-coupled receptors. Elife 7(2018).

Roth 

Bradykinin and inflammatory pain

Cardiovascular hypertrophy: role of angiotensin II and bradykinin

The kallikrein-kinin system in diabetic nephropathy

Bradykinin receptor ligands: therapeutic perspectives

Bifunctional ligands of the bradykinin B2 and B1 receptors: An exercise in peptide hormone plasticity

A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm

Pulmonary edema in COVID-19: Explained by bradykinin?

Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome

Proc Natl International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences

Site-directed mutagenesis at the human B2 receptor and molecular modelling to define the pharmacophore of non-peptide bradykinin receptor antagonists

New insights into the stereochemical requirements of the bradykinin B1 receptor antagonists binding

New insights into the stereochemical requirements of the bradykinin B2 receptor antagonists binding

The structure of the neuropeptide bradykinin bound to the human G-protein coupled receptor bradykinin B2 as determined by solid-state NMR spectroscopy

The molecular basis of subtype selectivity of human kinin G-protein-coupled receptors

Molecular features characterizing non-peptide selectivity to the human B1 and B2 bradykinin receptors

Cryo-EM structure of an activated VIP1 receptor-G protein complex revealed by a NanoBiT tethering strategy

A unique hormonal recognition feature of the human glucagon-like peptide-2 receptor

Structural basis for activation of the growth hormone-releasing hormone receptor

Mini-G proteins: Novel tools for studying GPCRs in their active conformation

Structure of the mu-opioid receptor-Gi protein complex

Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin

The Cryo-EM data of bradykinin-B2R-Gq complex were collected at Cryo-Electron Microscopy Research Center, Shanghai Institute of Material Medica. Cryo-EM data collection of des-Arg 10 -kallidin-B1R-Gq was carried out at the Shuimu BioSciences Ltd. We thank all the staff at these two cryo-EM facilities for their technical support. This work was partially 

All data is available in the main text or the supplementary materials. Materials are available from the corresponding authors upon reasonable request.